Clinical Takeaway
In this small pilot trial, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time in adults with diagnosed insomnia disorder, suggesting that this cannabinoid combination did not improve and may have worsened objective sleep in this population. High-density EEG findings indicate measurable changes in sleep architecture, and next-day alertness effects were also detected. Patients and clinicians should be cautious about assuming cannabinoids reliably improve sleep, as outcomes may depend heavily on dose, ratio, and individual factors.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first objective neurophysiological characterization of combined oral THC/CBD effects on sleep architecture in clinically diagnosed insomnia using high-density EEG, filling a critical evidence gap between widespread clinical use and limited mechanistic data. Understanding how this specific cannabinoid formulation alters sleep stages and next-day cognitive function is essential for establishing evidence-based dosing recommendations and identifying which insomnia phenotypes might benefit from cannabinoid therapy versus alternative interventions.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study offers valuable objective neurophysiological data on a commonly used cannabis formulation for insomnia, yet several important limitations merit consideration before clinical application. The small sample size of 20 participants, predominance of female subjects, and single-dose design limit generalizability and our ability to assess safety or efficacy across diverse populations or longer treatment courses. The specific THC to CBD ratio tested (10:200 mg) may not reflect typical patient dosing patterns or available products, and the absence of reported outcomes on next-day cognition or impairment risk represents a significant gap for patients concerned about functional impact. While high-density EEG provides mechanistic insight into sleep architecture that standard polysomnography cannot, clinicians should recognize this is exploratory evidence rather than definitive guidance. Given the modest evidence base and individual variability in cannabinoid metabolism and response, a reasonable clinical approach remains judicious trial of lower-dose formulations in carefully selected insomnia patients with documented sleep disturbance, close monitoring for da
| |